Pembrolizumab Monotherapy
Phase 3Active 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Head and Neck Cancer
Conditions
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
Trial Timeline
May 30, 2025 → Feb 1, 2029
NCT ID
NCT06790966About Pembrolizumab Monotherapy
Pembrolizumab Monotherapy is a phase 3 stage product being developed by PDS Biotechnology for Recurrent Head and Neck Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06790966. Target conditions include Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06790966 | Phase 3 | Active |
Competing Products
20 competing products in Recurrent Head and Neck Cancer